17, 2008 - Progenics Pharmaceuticals, Inc., today announced the Therapeutic Goods Administration division of the Australian Government has approved the registration of RELISTOR(methylnaltrexone bromide 12mg/0.6ml solution for injection) for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care when response to laxative therapy has not been sufficient.
The details can be read here.
No comments:
Post a Comment